In today’s business climate, medical device and life sciences companies need to be properly positioned at each phase of development with the appropriate plans in place for later portfolio development stages. Panelists will review key business and intellectual property management tools and strategies that are needed at the early-, mid- and late-growth stages as well the types of funding needed to fuel growth throughout the product life cycle. We also will address how and when you should plan for an IPO as well as other exit strategies, including merger and acquisitions.
Topics include:
- How companies can balance the need to continually innovate while minimizing the failure rate
- How to realize revenue streams earlier in the process
- How to evaluate innovation based on potential business value
Panelists:
- Jeff Draa, Board of Directors, Tech Coast Angels
- Gabor Garai, Partner, Foley & Lardner
- Vanessa Herbert, Senior Manager, PricewaterhouseCoopers
- Keith Lindenbaum, Partner, Foley & Lardner LLP
- Robert Mashal, M.D., President & CEO, NKT Therapeutics
- David Parrot, M.B.A., Managing Director, BMO Capital Markets Corp.
Related Insights
December 19, 2025
Health Care Law Today
Gender Affirming Care for Minors: CMS and HHS Propose Limits on “Sex Rejection Procedures” and Expanded Enforcement Pathways
On December 18, 2025, the U.S. Department of Health and Human Services (HHS) held a press conference focused on what is defined as “sex…
December 19, 2025
Foley Viewpoints
Prohibition to Prescription: What Trump’s Marijuana Executive Order Really Means
On December 18, 2025, President Donald Trump issued an Executive Order, Increasing Medical Marijuana and Cannabidiol Research, that…
December 18, 2025
Manufacturing Industry Advisor
Foley Automotive Update
Analysis by Julie Dautermann, Competitive Intelligence Analyst Foley is here to help you through all aspects of rethinking your long-term…